Ebola vaccine being tested in DR Congo outbreak zone

The Hindu – International

You are logged in

Loading…

You don’t have any Active Subscription.

Subscribed with another email? Logout and Login with that one.

Your active subscription(s)

Account subscription benefits alongside Premium Stories, Editorials,
Opinions and more. Unlock these with Subscription

Products you’ve access to

Additional Subscription Benefits

Account Settings

Need help with your subscription?

Weather News September 20, 2026 e-Paper

The View From India
Looking at World Affairs from the Indian perspective.

First Day First Show
News and reviews from the world of cinema and streaming.

Today's Cache
Your download of the top 5 technology stories of the day.

Science For All
The weekly newsletter from science writers takes the jargon out of science and puts the fun in!

Data Point
Decoding the headlines with facts, figures, and numbers

THEdge
At the cutting edge of education and careers

Health Matters
Ramya Kannan writes to you on getting to good health, and staying there

Gender Agenda
Stories from beyond the binary.

The Hindu On Books
Books of the week, reviews, excerpts, new titles and features.

Weather News September 20, 2026 e-Paper

Published – September 20, 2026 10:12 pm IST – Bunia, DR Congo

A healthcare worker holds up a vial of the Ervebo vaccine at an Ebola vaccination centre in the city of Bunia, Ituri province, Congo.
| Photo Credit: AP

Health workers in parts of the DR Congo, badly hit by a deadly Ebola outbreak, launched a test vaccination programme on Saturday (September 20, 2026) to see if jabs designed for a different strain of the virus could prove effective in this case.

The operation, backed by the World Health Organization and the Doctors Without Borders (MSF) charity, will see 20,000 frontline health personnel given the Ervebo vaccination in the Ituri and North-Kivu provinces, in a study lasting up to a year.

The current Ebola epidemic in the Democratic Republic of Congo has killed 3,639 people out of 7,541 confirmed cases, according to the latest figures from the country's authorities. That is a fatality rate of 48.3%.

It is caused by the Bundibugyo strain of the virus, for which there is currently no approved vaccine or treatment.

The vaccination being rolled out as of this weekend was developed for use against the Zaire strain, and the study will determine how effective it might be against the Bundibugyo strain.

"We don't know to what degree it might be effective against the Bundibugyo strain," said Steve Ahuka, a Congolese official who is part of the health task force against the Ebola outbreak.

"It might offer a certain level of cross-protection against the Bundibugyo virus," said Nana Mimbu, an MSF research coordinator.

While WHO officials have cited "encouraging signs" that transmission may be slowing, MSF warned on Friday (September 18, 2026) that there was no clear evidence that the epidemic was coming under control.

WHO experts have said that early data on the Ervebo vaccine, notably from animal trials, suggested it could offer some protection in the current outbreak.

The UN health agency said last month that 70,000 doses of the vaccine, developed by the pharmaceutical company Merck and produced in Germany, were to be sent to the DRC.

AFP journalists on Saturday (September 19, 2026) saw health workers in Bunia, the main city of Ituri province, receiving vaccinations.

Published – September 20, 2026 10:12 pm IST

health

/

disease

Terms & conditions | Institutional Subscriber

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.

Fonte: The Hindu – International